Skip to main content
ALGN logo

Align Technology, Inc. (ALGN) Stock: Price, Forecast & Analyst Target

Align Technology, Inc. (ALGN) — MoonshotScore 83/100 (Exceptional band), calculated Nov 18, 2026. Price $163.96 (+0.31%), as of the Nov 18, 2026 trading session; market cap $11.6B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 10.13× (cash as of Sep 30, 2026) · expected results Feb 3, 2027

$163.96 +$0.50 (+0.31%) Market Cap $11.6B

Align Technology, Inc. · ALGN · NASDAQ · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-13: Align Technology sells Invisalign treatment products and iTero scanning hardware, software and services to dental professionals, with clear aligners supplying the dominant share of revenue. Its economics depend more on clinician-started treatment cases and the price earned per case than on scanner shipments alone. Recent sales progress matters only if it translates into firmer profit while lower selling prices and restructuring costs press margins.

Price as of Nov 18, 2026

Key Statistics

83 of 100

MoonshotScore v2 · Align Technology (ALGN)

Exceptional
Business Quality Elite (88)
Financial Safety Sound (74)
Valuation Fair (65)
Growth Durability Flat (53)
Momentum Rising (78)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and a strong balance sheet, though growth is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.

  • quarterly revenue $996M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 5 of the last 8 reports
  • expected results Feb 3, 2027

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ALGN (57 recorded, newest six shown)
RecordedScoreBand
80Exceptional
81Exceptional
81Exceptional
81Exceptional
83Exceptional
83Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$163.96
Change on the day+0.31%
52-week range$130.23–$200.44
Market capitalisation$11.6B—
Price / earnings (trailing)23.76
Shares traded on the day892.0K
Beta (volatility vs the S&P 500)1.74

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $130, high $190, latest $164. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $190 $130 high $190 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $1881Apr 29, 2026 · Earnings results · reported above the recorded estimate · close $1792Jul 29, 2026 · Earnings results · reported above the recorded estimate · close $1693Oct 28, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $1504Oct 28, 2026 · Earnings results · reported above the recorded estimate · close $1505 Oct 17, 2025 Nov 18, 2026 · $164 $130Oct 17, 2025$138Oct 31, 2025$137Nov 14, 2025$147Nov 28, 2025$165Dec 12, 2025$158Dec 26, 2025$173Jan 9, 2026$169Jan 23, 2026$188Feb 6, 2026$190Feb 20, 2026$174Mar 6, 2026$173Mar 20, 2026$171Apr 2, 2026$190Apr 17, 2026$179May 1, 2026$157May 15, 2026$175May 29, 2026$175Jun 12, 2026$178Jun 26, 2026$179Jul 10, 2026$167Jul 24, 2026$174Aug 7, 2026$163Aug 21, 2026$159Sep 4, 2026$148Sep 18, 2026$144Oct 2, 2026$147Oct 16, 2026$150Oct 30, 2026$168Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • For fiscal 2026, we expect 2026 worldwide revenue to be approximately $4.11 billion to $4.13 billion.

    John Morici · Statement from

  • We continue to expect 2026 Clear Aligner volume and revenue growth to be up approximately 5% to 6% year-over-year.

    John Morici · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Align Technology (ALGN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Moderate
Growth Durability Neutral
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Strong
ROE Neutral
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Align Technology (ALGN), and what does it report?

Short answer · as of

Align is not chiefly a dental-equipment vendor.

Invisalign offerings span comprehensive and limited treatments, retainers, training and clinical accessories, while iTero combines scanners with diagnostic, treatment-planning and restorative applications. Reported revenue therefore blends case-based treatment products with scanner hardware, software and related services, although clear aligners remain the much larger business.

2 · Latest results

What do the latest results show for Align Technology (ALGN)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $996M.

Revenue edged higher in the latest period, yet gross profit, operating income, net income and diluted earnings weakened from the preceding period. The longer record tells a similar story: annual sales have advanced gradually while net profit has remained below its earlier peak, even as reported revenue and earnings have generally cleared recent consensus expectations. Management expects further near-term margin pressure from lower average selling prices, accelerated depreciation, restructuring and related charges; that outlook describes the coming pressure rather than explaining the latest result.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$1.01B Sep 30, 2026
Latest quarter · R&D
$93.87M Sep 30, 2026
Latest quarter · SG&A
$410.55M Sep 30, 2026
Latest quarter · FMP standardized operating result
$169.16M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$1.01B$93.87M$410.55M$169.16M
Jun 30, 2026$1.06B$102.03M$462.67M$123.30M
Mar 31, 2026$1.04B$98.66M$465.34M$172.67M
Dec 31, 2025$1.05B$83.04M$440.74M$159.59M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.01B Oct 28, 2026
Latest report · revenue estimate
$1.00B Oct 28, 2026
Latest report · revenue vs estimate
Above estimate Oct 28, 2026
Latest report · EPS vs estimate
Above estimate Oct 28, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 28, 2026$1.01B$1.00B$2.8000$2.7700
Jul 29, 2026$1.06B$1.05B$2.6400$2.6200
Apr 29, 2026$1.04B$1.02B$2.5800$2.3000
Feb 4, 2026$1.05B$1.03B$3.2900$2.9900
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$996M$57M$0.78 (diluted)
Q4 FY2025$1.05B$136M$1.89 (diluted)
Q1 FY2026$1.04B$113M$1.57 (diluted)
Q2 FY2026$1.06B$108M$1.52 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Align Technology (ALGN)?

Short answer

Cash and short-term investments were $1.14B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $182.92M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Cash and short-term investments materially exceed total debt, liquidity ratios remain above parity, and operating cash flow has stayed positive throughout the reported series. Cash also recovered after an earlier decline, leaving Align with meaningful capacity to absorb restructuring costs and continue product development. The operating risk sits in clear-aligner economics: because that segment generates most revenue, sustained price pressure would weigh on gross profit unless treatment demand or product mix compensates.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$182.92M Sep 30, 2026
Previous quarter · operating cash flow
$192.76M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$182.92M−$45.03M
Jun 30, 2026$192.76M−$35.66M
Mar 31, 2026$151.04M−$30.78M
Dec 31, 2025$223.18M−$35.92M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Align Technology (ALGN)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027.

At the coming release, compare revenue with the recent run rate and the expected sequential step-down, then separate underlying profitability from the charges management has identified. Management expects reported margins to absorb restructuring and accelerated depreciation while presenting materially stronger adjusted-margin expectations, making the gap between those measures especially important. Cash conversion is another useful check: operating cash flow recovered from its earlier trough and cash increased, so a reversal alongside weaker profit would alter the financial picture.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. We expect 2026 Systems and Services revenue to be $715 million to $725 million.

    John Morici ·

  2. We expect 2026 GAAP operating margin to be approximately 16.2%, up approximately 2.7 points year-over-year.

    John Morici ·

2 more statements are quoted under Upcoming events

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Nov 5, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Align Technology compare with its peers?

Short answer

Align Technology's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a pure scanner vendor, Align has a case-based treatment engine whose revenue depends on clinicians initiating Invisalign therapies and selecting among treatment packages. Compared with a pure orthodontic-product company, iTero adds scanner hardware, clinical software, digital records and restorative workflows. That pairing broadens the clinician relationship, but clear aligners remain dominant enough that scanner success alone cannot determine companywide performance.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Named competitor$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
Globus Medical, Inc. (GMED) Named competitor$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Named competitor$320.50 Nov 18, 2026$12.6B92 5-pillar Nov 18, 2026
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$404.02 Nov 18, 2026$28.1B92 5-pillar Nov 18, 2026
Align Technology (ALGN) — this page$163.96$11.6B83
Haemonetics Corporation (HAE) Same industry, near in market value$122.86 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$85.93 Nov 18, 2026$5.15B81 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Same industry, near in market value$141.67 Nov 18, 2026$8.98B77 5-pillar Nov 18, 2026
The Ensign Group, Inc. (ENSG) Named competitor$182.98 Nov 18, 2026$10.7B74 5-pillar Nov 18, 2026
Repligen Corporation (RGEN) Same industry, near in market value$172.67 Nov 18, 2026$11.0B71 5-pillar Nov 18, 2026
Avantor, Inc. (AVTR) Same industry, near in market value$15.37 Nov 18, 2026$10.4B71 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$165.85 Nov 18, 2026$6.58B61 5-pillar Nov 18, 2026
BioMarin Pharmaceutical Inc. (BMRN) Named competitor$61.43 Nov 18, 2026$11.9B58 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$162.00 – $215.00
Consensus target
$190.00
Median target
$189.00

Consensus record · Captured .

Measured against a quoted price of $163.96 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
5
Purchases
0
Sales
0
Other transactions
12

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
641 Period end Sep 30, 2026
Previous quarter · holders
712 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Fmr LLC5,527,912
Blackrock, INC.4,482,335
Capital International Investors4,479,009
Vanguard Capital Management LLC4,365,915
Capital World Investors3,632,336

Tracked investors

Which of the 16 named investors we follow held ALGN in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.07%$15.87MAdded +32.5% shares
ARK InvestCathie WoodQ3 20260.00%$794,628Added +3.9% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Align Technology (ALGN)?

Read these with our analysis →

ALGN Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

Why does Invisalign case activity matter more than iTero scanner sales for Align Technology?

Clear aligners contribute most of Align’s segment revenue, so treatment starts, package selection and case pricing carry greater weight in companywide results. iTero remains strategically relevant because its scanning and clinical applications sit inside the dental workflow.

Why can lower Invisalign selling prices hurt Align Technology when revenue holds up?

Stable or rising revenue can coexist with weaker profit when Align earns less per case or incurs higher operating costs. The latest results already show revenue improving while gross profit and operating income declined, and management expects lower selling prices to remain a margin pressure.

How will restructuring affect Align Technology’s coming margins?

Management expects accelerated depreciation, restructuring and related charges to depress reported gross and operating margins. Adjusted expectations exclude much of that burden, so the durability of profitability is clearer when reported and adjusted outcomes are considered together.

Does Align Technology need heavy borrowing to support Invisalign and iTero investment?

Cash and short-term investments substantially exceed debt, while operating cash flow has remained positive across the reported periods. That gives Align room to fund research, product development and restructuring without making borrowing the central source of financial capacity.

What is the ALGN stock price today?

The last price recorded for Align Technology, Inc. (ALGN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ALGN price target?

The analyst consensus price target for Align Technology, Inc. (ALGN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 77 figures on this page — 1 from SEC filings and earnings calls, 69 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • 1. What is Align Technology (ALGN), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Align Technology (ALGN)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Align Technology (ALGN)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Revenue by segment; Quarterly income statement (USD thousands)
  • 4. What should you watch next at Align Technology (ALGN)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 5. How does Align Technology compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • FAQ: Why does Invisalign case activity matter more than iTero scanner sales for Align Technology?: Business description; Revenue by segment
  • FAQ: Why can lower Invisalign selling prices hurt Align Technology when revenue holds up?: Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • FAQ: How will restructuring affect Align Technology’s coming margins?: Management outlook — dated call excerpts
  • FAQ: Does Align Technology need heavy borrowing to support Invisalign and iTero investment?: Cash, investments and debt; Cash and investment components; Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ALGN

Funds in our ETF coverage that list ALGN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Simplify Health Care ETF (PINK)8.11%
Virtus KAR Mid-Cap ETF (KMID)3.74%
Alger Russell Innovation ETF (INVN)2.71%